Paliperidone

Evidence Level: L5

Predicted Indications: 9

Paliperidone

Pharmacist Assessment Report

Paliperidone: From Schizophrenia to Retinal Dystrophy with or without Extraocular Anomalies

One-Sentence Summary

Paliperidone is an atypical antipsychotic originally used for schizophrenia and related psychotic disorders. The TxGNN model predicts it may be effective for retinal dystrophy with or without extraocular anomalies, but no clinical trials and no publications currently support this direction. It is a model prediction only.

Quick Overview

Item	Content
Original Indication	Schizophrenia, schizoaffective disorder, schizophreniform disorder and other psychotic disorders
Predicted New Indication	Retinal dystrophy with or without extraocular anomalies
TxGNN Prediction Score	0.9992
Evidence Level	L5
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the data compiled for this report. Paliperidone is the active metabolite of risperidone (9-hydroxyrisperidone). It is generally understood to act through dopamine D2 and serotonin 5-HT2A receptor antagonism, and its efficacy in schizophrenia is established.

A plausible mechanistic link to inherited retinal degeneration is not evident. Retinal dystrophies are typically driven by genetic defects in photoreceptor or retinal pigment epithelium function, and nothing in the data connects D2/5-HT2A antagonism to those pathways. The very high TxGNN score (0.9992) is therefore best treated as a likely TxGNN model (deep learning) artefact rather than a credible repurposing signal. Treat it as a hypothesis only.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Australia Market Information

ARTG Number	Product Name	Dosage Form
11066K	Invega Trinza	I.M. injection (modified release) 525 mg (as palmitate) in pre-filled syringe

The only registered presentation is a long-acting intramuscular injection. Compatibility of this route with a retinal indication has not been assessed.

Safety Considerations

Contraindications and cautions from the knowledge graph (drug-disease relationships, not label text). The following conditions are flagged as contraindicated or requiring caution:
- Cardiovascular: long QT syndrome (including familial), torsades de pointes, orthostatic hypotension, postural orthostatic tachycardia syndrome, hypotensive disorder, myocardial infarction, coronary thrombosis
- Neurological: epilepsy, multiple system atrophy, basal ganglia disease, focal hand dystonia, blepharospasm
- Metabolic: diabetes mellitus, hyperglycaemia, diabetic ketoacidosis, hyperlipidaemia (including familial), obesity disorder (including monogenic), potassium deficiency
- Haematological: neutropenia, agranulocytosis, haemoglobinopathy
- Gastrointestinal: Crohn disease, Crohn’s colitis, inflammatory bowel disease
- Other: female breast carcinoma, impaired renal function
Drug Interactions: 100 interactions were recorded. Those reviewed include two major interactions, with bupropion and morphine. Many moderate interactions were also listed, including:
- antidiabetic agents: acarbose, metformin, pioglitazone, alogliptin, albiglutide, canagliflozin, chlorpropamide
- anticholinergic or antimotility agents: atropine, hyoscyamine, glycopyrronium, loperamide
- other agents: epinephrine, hydrocortisone, famotidine, amphotericin B, lorcaserin, bisacodyl

Product-specific warnings and contraindications were not available. Please refer to the TGA-approved Product Information (PI) for full safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction rests solely on a model score. There are no registered trials, no publications and no plausible mechanistic link between paliperidone and inherited retinal degeneration. A long-acting antipsychotic injection with a notable cardiometabolic and neurological safety profile is an unlikely fit for this condition.

To proceed, the following is needed:

Preclinical or mechanistic evidence linking dopaminergic or serotonergic signalling to retinal dystrophy pathology
Detailed mechanism of action data for paliperidone
Evaluation of route and formulation suitability for an ocular or retinal indication
Product Information review of warnings and contraindications

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.